Royalty Pharma, Denali Therapeutics partner for $275 mln tividenofusp alfa funding

• Royalty Pharma and Denali Therapeutics announce $275 million synthetic royalty funding agreement • Tividenofusp alfa, Denali's lead investigational treatment for mucopolysaccharidosis type II (MPS II), is under FDA review • FDA target date for Prescription Drug User Fee Act (PDUFA) is April 5, 2026 • Royalty Pharma acquires royalty on tividenofusp alfa, addressing unmet need in Hunter syndrome treatment • Denali's TransportVehicleTM-enabled enzyme replacement therapy has potential for cognitive and physical benefits.